5.03
+0.45(+9.83%)
Currency In USD
| Previous Close | 4.58 |
| Open | 4.61 |
| Day High | 5.58 |
| Day Low | 4.61 |
| 52-Week High | 19.3 |
| 52-Week Low | 1.08 |
| Volume | 688,957 |
| Average Volume | 2.47M |
| Market Cap | 33.67M |
| PE | -0.86 |
| EPS | -5.87 |
| Moving Average 50 Days | 4.06 |
| Moving Average 200 Days | 2.38 |
| Change | 0.45 |
If you invested $1000 in Sonnet BioTherapeutics Holdings, Inc. (SONN) 10 years ago, it would be worth $0 as of October 02, 2025 at a share price of $5.03. Whereas If you bought $1000 worth of Sonnet BioTherapeutics Holdings, Inc. (SONN) shares 5 years ago, it would be worth $0.37 as of October 02, 2025 at a share price of $5.03.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sonnet to Present at the MedInvest Biotech & Pharma Conference
GlobeNewswire Inc.
Sep 19, 2025 1:00 PM GMT
Live webcast presentation on Thursday, September 25th at 9:40 AM PTPRINCETON, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherap
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
GlobeNewswire Inc.
Aug 04, 2025 12:40 PM GMT
Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) Topline safety, cytokine, and efficacy data suggest a strong pote
Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy
GlobeNewswire Inc.
Jul 14, 2025 10:00 AM GMT
Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasuryPRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced t